home / stock / ktta / ktta news

KTTA News and Press, Pasithea Therapeutics Corp. From 02/23/23

Stock Information
Company Name: Pasithea Therapeutics Corp.
Stock Symbol: KTTA
Market: NASDAQ
Website: pasithea.com
Menu
KTTA KTTA Quote KTTA Short KTTA News KTTA Articles KTTA Message Board
Get KTTA Alerts

News, Short Squeeze, Breakout and More Instantly...
KTTA - Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)

PALO ALTO, Calif. and MIAMI, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous System (CNS...
KTTA - Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

PALO ALTO, Calif. and MIAMI, Fla., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research, and development of innovative treatments for Central Nervous Syste...

KTTA - Pasithea stock rises on contract with WuXi to make PAS-004

Pasithea Therapeutics ( NASDAQ: KTTA ) signed a contract with WuXi STA to manufacture the active pharmaceutical ingredient (API) for Pasithea's PAS-004. Pasithea plans to start a phase 1 trial of PAS-004 (formerly CIP-137401) in the U.S. to treat Neurofibromatosis t...

KTTA - Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

-- Plans to Initiate a Phase 1 Clinical Trial in the U.S. for Neurofibromatosis Type 1 (NF1) in 2H 2023 -- MIAMI BEACH, Fla., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company...
KTTA - Majority of Stockholders Support Pasithea Directors at Special Meeting

MIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders...

KTTA - Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

MIAMI BEACH, Fla., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders...

KTTA - Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

MIAMI BEACH, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for Central Nervous System (CNS) disor...
KTTA - Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time

MIAMI BEACH, Fla., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (“...

KTTA - Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Believes Removing All Incumbent Directors Will Position Pasithea to Enhance Corporate Governance, Improve Capital Allocation and Deliver Long Term Value Urges Stockholders to Vote for ALL Proposals on the WHITE Proxy Card at Pasithea’s November 29 th Special...

KTTA - A New BioTech Research Race Is Focused On Improving Life For MS Patients

(NewsDirect) Learn More about Pasithea Therapeutics by gaining access to the latest research report When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no known cure can be hidden from the public consci...
Previous 10 Next 10